
DRAFT FOR CONSULTATION, August 2017

Draft: 11 August 2017

The Global Action Plan (GAP) on Antimicrobial Resistance (AMR) has been endorsed by all countries as a cross-sectoral approach to address the threat of AMR. Political leaders in the United Nations General Assembly (UNGA) special session further endorsed it in their Political Declaration on AMR in September 2016.

The GAP sets out responsibilities for national governments, for the World Health Organization (WHO), the Food and Agriculture Organization of the United Nations (FAO), the World Organisation for Animal Health (OIE) and for other national and international partners involved in the global response to AMR. To ensure action is being taken, and to assess whether those actions are having the intended results, monitoring and evaluation (M&E) is required. Therefore, the “One Health” tripartite organisations - WHO, FAO and OIE - have come together to develop the joint M&E approach documented here.

The aim is to develop a manageable system that will generate useful data to inform operational and strategic decision making on AMR for the next five to ten years. The approach and framework described in this paper are based on experience in tackling AMR in the human and animal health sectors. As action in other sectors (such as the environment and plant health) develops, the monitoring approach and framework can be further elucidated. The M&E approach recognises that countries are at very different stages of planning and delivering their responses to AMR; M&E capacity and systems need to be built and strengthened alongside implementation of the response.

This draft paper outlines current thinking of the tripartite on the approach to M&E of the GAP on AMR and the resulting global response to AMR. To date, this M&E approach has benefitted from consultation with external experts. This version is being circulated more widely through an open online consultation which solicits feedback from countries and institutions with an interest in AMR control and GAP implementation at national and international levels. Please respond through http://www.who.int/antimicrobial-resistance/en/
Contents
Acronyms ........................................................................................................................................... 3
Executive Summary .................................................................................................................................. 4
1. Purpose of this paper .......................................................................................................................... 8
2. Overall framework for M&E of the GAP on AMR ............................................................................. 9
3. Monitoring and evaluating the process of GAP implementation: activities and outputs .............. 12
4. Monitoring and evaluation of outcomes and goals ........................................................................... 14
5. Next steps ......................................................................................................................................... 17
Annex 1: Summary of results chain for GAP and the response to AMR ........................................... 19
Annex 2: Global level monitoring of outputs ......................................................................................... 20
Annex 4: Proposed General Outcome and Goal Indicators .................................................................. 27

Acronyms
AM .............................................................. Antimicrobial
AMR ............................................................ Antimicrobial resistance
AST ............................................................. Antimicrobial susceptibility test
ATLASS ......................................................... Assessment Tool for Laboratory and AMR Surveillance System (FAO)
CIA .............................................................. Critically Important Antimicrobials
ESBL ............................................................ Extended-spectrum beta-lactamase
FAO .............................................................. Food and Agriculture Organization of the United Nations
GAP .............................................................. Global Action Plan
GLASS ......................................................... Global AMR Surveillance System
HAI .............................................................. Health-care associated infections
ICD .............................................................. International Classification of Diseases
IHR .............................................................. International Health Regulations
IPC .............................................................. Infection prevention and control
JEE .............................................................. Joint External Evaluation
M&E ............................................................ Monitoring and Evaluation
MRSA ........................................................ Methicillin-resistant Staphylococcus aureus
NAP .............................................................. National Action Plan on AMR
OIE ............................................................. World Organisation for Animal Health (original name Office International des Epizooties)
PVS ............................................................ Performance of Veterinary Services
R&D ............................................................ Research and Development
UNEG ........................................................ United Nations Evaluation Group
UNGA ........................................................ United Nations General Assembly
VPH ............................................................ Veterinary Public Health
VRE ............................................................ Vancomycin-resistant enterococci
WASH ........................................................ Water, sanitation and hygiene
WHA ............................................................ World Health Assembly
WHO ............................................................ World Health Organization
**Executive Summary**

The Global Action Plan (GAP) on Antimicrobial Resistance (AMR) was adopted by the World Health Assembly (WHA) in May 2015. It was also supported through decisions of the governing bodies of the Food and Agriculture Organization of the United Nations (FAO) and the World Organisation for Animal Health (OIE) in 2015. In 2016, the United Nations General Assembly (UNGA) reaffirmed the GAP as the blueprint for tackling AMR and heads of state committed to work at global, regional and national levels in line with the GAP. The GAP sets out five strategic objectives to address AMR, with the goal of ensuring, for as long as possible, continued ability to treat and prevent infectious diseases with effective and safe medicines that are quality-assured, used in a responsible way, and accessible to all who need them. This should result in fewer deaths and a reduction in morbidity resulting from infections affected by AMR.

This paper summarises the approach proposed for monitoring and evaluation (M&E) of both the implementation of the GAP and the resulting effects on AMR and on health. M&E is required at both national and global levels; for management, to identify and respond to barriers to progress, and to inform course correction, in order to increase impact and value for money. M&E is also needed for accountability, within countries and at regional and global levels. This includes reporting back to the global health community, including the governing bodies of WHO, FAO and OIE, and the Interagency Coordination Group on AMR that was established by the UN General Assembly.

AMR is an inter-sectoral issue that requires action across sectors, as described in the GAP. This paper is written from a tripartite (WHO, FAO and OIE) perspective, reflecting the need to monitor activity within human and animal health, plant production and the environment, and the role of the tripartite in supporting and enabling progress on implementation of the GAP.

In developing the M&E plan for the GAP, the following principles are proposed:

- In view of the multi-sectoral nature of AMR, it would be useful to establish standard measures of goals and outcomes across humans, animals, plants and the environment, and coordinate monitoring and reporting.
- In developing national action plans on AMR (NAPs), countries set their own targets that suit the country context. Global targets may be established at a later stage. The M&E approach described in this paper therefore does not include national or global targets.

- Whilst there will be some indicators that are relevant across countries, countries are starting from very different points in their capacity to address AMR and monitor progress as well as in their resources and capacity for doing so. Expectations and proposed indicators should take this into account.
- The M&E process should use existing systems where possible, and strive to minimize the burden of additional data requirements.

M&E requirements can be split into two broad elements. The approach is summarised in Figure 1:

- Monitoring the process of GAP implementation and evaluating how to improve the response: how far are AMR national action plans being developed and implemented, how are international organisations playing their roles, are planned outputs being achieved?
• Monitoring outcomes and evaluating the results at outcome and goal levels: including trends in AMR, appropriate antimicrobial use, incidence of infections and influence on mortality.

Figure 1: Summary of M&E components for the GAP on AMR

Key elements of the M&E approach include the following:

1. Monitoring country progress with developing and implementing their NAPs on AMR starts at the country level. Countries are expected to develop an appropriate M&E plan as part of their One Health NAP, tailored to their particular plan and priorities. For countries at an early stage of developing their response, monitoring may focus on output measures as key indicators of progress, while building capacity for measuring outcomes. The M&E plan should also address how monitoring will take place, such as an annual review of progress.

2. Global level monitoring of country progress on addressing AMR is planned to occur on an annual basis; it began with the first global AMR monitoring survey in 2016/17.

3. WHO, FAO and OIE will conduct routine monitoring of their own planned activities and the outputs achieved, against each organisation’s plan and budget on AMR. The recently-formed Interagency Coordination Group on AMR may establish further reporting requirements or independent monitoring of tripartite progress.

4. There are benefits to having standard indicators for the specific outcomes of AMR-related strategies at national level that can also be compared across countries. Draft indicators are included (see annex 3) for consultation.

5. For global monitoring and reporting, standard measures are needed of resistance levels and appropriate use of antimicrobials. This will draw on work underway to strengthen national and global data and reporting on AMR and antimicrobial use, including the Global Antimicrobial Resistance Surveillance System (GLASS) which is starting with data on AMR among humans; FAO’s Assessment Tool for Laboratory and AMR Surveillance Systems (ATLASS) approach to build capacity for AMR data in animals; and OIE data collection on the use of antimicrobial agents in animals. Draft indicators are included for consultation (see Annex 4).

6. Evaluation of progress against the goals will require modelling to assess health impact of AMR and estimate the effect of the measures implemented.
7. An independent formative evaluation is proposed for 2018, focussing on lessons from implementation of GAP at country, regional and global levels. This could provide the basis for the report to UNGA in 2018/19. The evaluation could be commissioned jointly by a group of interested partners or by the Interagency Coordination Group.

8. A more extensive evaluation is proposed after about 5 years, if funds allow, preferably jointly commissioned and funded by several partners. This evaluation would identify why results have been achieved (or why they have not) and assess how to increase impact.

Figure 2 summarises the proposed M&E structure and approach by level of activity and flows of information.

**Figure 2 Overview of proposed M&E approach**

The next steps are to:

- Share the proposed M&E approach widely via an online public consultation, to gather views and inputs from countries and interested institutions and revise the approach in light of feedback.
- Further develop/refine the AMR M&E indicators, following the feedback from this consultation.
- Provide advice/remote support to country-level monitoring of national action plans, through sharing lessons and indicators and/or setting up a global community of practice as appropriate. If resources allow, this could include sharing species-specific experiences on efficient implementation of standards and practices to reduce use of antimicrobials.
- Publicise the baseline findings of the first round of global monitoring of country progress on AMR (results available online) to interested parties. Update the questionnaire underpinning the global AMR monitoring survey before implementation of the 2017/2018 round of data collection beginning in the last quarter of 2017.
• Continue work with regional agencies to coordinate monitoring approaches and reporting on indicators.
• Define the scope of the formative evaluation proposed in 2018.
• Make recommendations on M&E to the Interagency Coordination Group on AMR.

For further information, please contact Pravarsha Prakash in the WHO AMR secretariat (prakashpra@who.int). She will link with FAO and OIE as needed.
1. Purpose of this paper

This paper sets out the approach and framework proposed for M&E of the GAP on AMR. It focuses on the need to monitor the processes of development and implementation of global and national action plans on AMR and to evaluate how far these are contributing to the outcomes and goals of controlling AMR. It sets out suggestions on indicators with a view to selecting the most feasible and appropriate after the consultation. The paper provides the basis for consultation with stakeholders interested in progress of the GAP and the global response to AMR.

To reflect the inter-sectoral nature of AMR, the paper was developed jointly by the One Health tripartite organisations (WHO, FAO and OIE) and identifies the approach to M&E across sectors. Some M&E\(^1\) activities and processes will be conducted jointly while others will be focused at sector level. What matters is that data is collected coherently, is shared, and is compatible and comparable across sectors.

Reporting on implementation and results will be required at various levels and to the global community. At country level, it is envisaged that there will be a review and reporting on progress against national action plans (NAPs) on AMR. Global level reporting includes data submission to: the WHA; the FAO governing bodies, (through reports to the Committee on Agriculture, agreed in FAO conference C 2015/28 Rev.1); the OIE General Assembly; and the United Nations General Assembly (UNGA).\(^2\)

The structure of this paper is as follows:

- **Section 2** lays out the overall M&E framework, which underlies the M&E approach and the choice of indicators.
- **Section 3** looks at monitoring and evaluating the implementation process and outputs – monitoring what progress has been made and whether planned outputs have been delivered, and formative evaluation to identify where remedial action is required.
- **Section 4** addresses M&E of the outcomes and goals – monitoring whether the intended outcomes are being achieved, and evaluating whether this is resulting in progress towards the goals of conserving effective medicines and reducing the impact of infectious diseases on health.
- **Section 5** outlines the next steps in finalising the approach and implementation.
- **Annex 1** sets out the results framework and annexes 2 to 4 give potential standard indicators at different levels.

---

\(^1\) This paper uses the definition of evaluation in the 2016 United Nations Evaluation Group (UNEG) Norms and Standards for Evaluation that states: “An evaluation is an assessment, conducted as systematically and impartially as possible, of an activity, project, programme, strategy, policy, topic, theme, sector, operational area or institutional performance. It analyses the level of achievement of both expected and unexpected results ……. An evaluation should provide credible, useful evidence-based information that enables the timely incorporation of its findings, recommendations and lessons into the decision-making processes of organizations and stakeholders.” Monitoring is defined as “systematic collection of data on specified indicators to provide management and stakeholders … with indications of the extent of progress, achievement of objectives and progress in use of allocated funds”. OECD DAC Glossary.

\(^2\) Political Declaration of the high-level meeting of the General Assembly on antimicrobial resistance, paragraph 15 requests a report to the 73rd session, UNGA Resolution A/Res/71/3, adopted 5 October 2016.
2. Overall framework for M&E of the GAP on AMR

2a. The Results Chain:

The GAP expects that all countries will develop their own NAPs on AMR in line with the global plan, and sets out 5 strategic objectives. The stated goal of the GAP is to ensure “continuity of the ability to treat and prevent infectious diseases with effective and safe medicines ....”. This goal contributes to the overarching goal of decreasing the impact of infectious diseases on human and animal health\(^3\). This overarching goal is more readily communicated than the stated goal of preserving the efficacy and safety of medicines, and links more directly to the Sustainable Development Goals.

Two general outcomes have been defined: to slow the development of resistance and to make more appropriate use of antimicrobials (including access when needed).

- Slowing development of resistance is intended to encompass delaying the emergence of resistance, slowing the spread and where possible, reversing trends to achieve a decline in resistance levels. Countries are at different stages and face different risks, and will need to define for their own context what are realistic targets for various pathogens and resistance mechanisms.
- More appropriate use includes reducing inappropriate use – whether this means incorrect use in terms of dosage or duration; use for the wrong purpose (e.g. antibiotics for viral diseases); use of poor quality medicines; and use of medicines important for human health to promote animal growth. It should take into account access to medicines when needed (for animal or human health).

The five specific outcomes in the framework relate directly to the five GAP strategic objectives. These are expected to contribute to the general outcomes and ultimately the goals.

On the human health side, monitoring and reporting related to drug resistance for HIV, TB and malaria already exists as part of the disease programmes in relevant countries. In view of this, for monitoring of GAP and AMR, the output monitoring survey and proposed outcome measures focus on antibiotics and resistance to them, and not on progress in addressing resistance in these three diseases\(^4\). For evaluating progress towards the goals, resistance in the three diseases should be included - as they contribute a significant share of the burden of resistance.

AMR in animal health currently focuses mainly on antibiotics; other antimicrobials will be progressively included. For plants and the environment, all types of antimicrobials are included.

Figure 3 sets out a results framework for M&E of the GAP and the resulting global response to AMR as a diagrammatic results chain, with the results statements outlined in more detail in annex 1. The figure proposes a set of summary outputs, specific and general outcomes, and goals related to the GAP.

---

\(^3\) Of course, action on AMR is only one component towards achievement of this overarching goal.

\(^4\) This focus on antibiotics relates to the monitoring approach – countries may identify synergies and opportunities for implementation of measures to address AMR that work with disease programmes as well as the broader health system.
This framework is not exhaustive, and there are other components that may be helpful to monitor for some purposes, such as the drivers of antibiotic consumption (burden of infectious disease, requirement for food production etc); unintended consequences and changes in legislative process.

2b. Roles and responsibilities for M&E

Multisectoral NAPs on AMR should be line with the global action plan. In order to gauge success and gather data that will inform programming decisions, countries will need to monitor implementation and assess the results of their NAPs. Therefore, countries are advised to develop an M&E plan for their NAPs, which will include country-appropriate indicators and – where possible – targets for output, outcome and goal levels. Each country should develop a set of indicators that is most appropriate to its particular setting and circumstances.

The NAP M&E will feed into the GAP M&E framework (see figure 2 above for the structure of M&E). The aim is to define a minimal set of indicators that are common to all countries, to provide an aggregated view of the AMR situation around the world and to enable comparisons over time and across geographic locations. Country-level data collection may be integrated with other systems.

Given that AMR-related M&E systems are not generally very advanced and therefore data availability is limited in countries at an early stage of the response to AMR, it may be most realistic to focus on monitoring outputs in the short term or using output-level proxies for the outcome level monitoring, whilst systems to measure outcomes and impact are developed.

Tripartite partners will regularly review country demand for experience-sharing and guidance around NAP monitoring indicators in their respective disciplines, and work with partners to respond to needs.

---

5 For example, use general health service availability surveys to monitor availability of antimicrobial medicines, water, sanitation and IPC measures in health facilities; and monitor adoption of Good Agricultural Practices and standards on responsible and prudent antimicrobial use in animals, including good husbandry and hygiene practices.
Figure 3: Overall framework for monitoring and evaluation of the AMR Global Action Plan

<table>
<thead>
<tr>
<th>Inputs</th>
<th>Activities</th>
<th>Outputs</th>
<th>Specific Outcomes</th>
<th>General outcomes</th>
<th>GAP Goal</th>
<th>Overarching goal</th>
</tr>
</thead>
<tbody>
<tr>
<td>Country stakeholder engagement</td>
<td>Develop &amp; implement national AMR plans</td>
<td>Awareness and understanding increased of AMR risks &amp; response</td>
<td>1. Improved awareness of AMR and behavior change among policymakers, farmers, vet &amp; health workers, food industry, general public</td>
<td>A. Slower development of resistance</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Situation analysis</td>
<td>Implement global actions &amp; plans</td>
<td>Training &amp; professional education on AMR</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>WHO, FAO &amp; OIE support, guidance &amp; standards</td>
<td></td>
<td>Strengthened veterinary services</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Other international and national partners’ action</td>
<td></td>
<td>Monitoring system on AMR use</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Funding</td>
<td></td>
<td>Surveillance system for AM resistance</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Technical expertise &amp; support</td>
<td></td>
<td>Research done on resistance &amp; use</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>IPC in human health care</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Good animal health &amp; management practices &amp; good hygiene to prevent infections &amp; reduce AM use</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>WASH &amp; immunization to reduce spread of infections in community</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Optimising antimicrobial use &amp; regulation</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Legislation / regulations to prevent environmental contamination with AM</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Estimates of funding needs &amp; economic case for investment</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Coordinated efforts, priorities &amp; incentives established for relevant R&amp;D</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Increased investment in R&amp;D to address AMR &amp; prevent infection</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Action on R&amp;D and economic analysis</td>
<td>Process and output monitoring</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

3. Monitoring and evaluating the process of GAP implementation: activities and outputs

The proposed approach to monitoring the process of GAP implementation and evaluating how to improve the response has 5 main elements:

3a. Monitoring country progress and outputs
3b. Monitoring progress of the tripartite organisations, WHO, FAO and OIE
3c. Monitoring progress on R&D coordination, incentive arrangements and making the economic case
3d. Monitoring investment in AMR responses
3e. Formative evaluation of the AMR response and how to improve it

3a. Monitoring country progress and outputs:
- As indicated above, countries will need to monitor progress on the activities and outputs in their NAPs, to support implementation of the NAP and report to national governance mechanisms.
- It is proposed to develop a “menu” of indicators from which the countries may choose, aligned with the global AMR monitoring survey. It is hoped that this menu will in the shorter term provide a foundation for effective country level M&E systems related to AMR, and in the longer term facilitate the collection of critical data on AMR globally.
- Monitoring at the global level of AMR-related outputs has started through the global AMR monitoring survey that summarises country capacity, coverage and performance on key aspects of the GAP. For this survey, a self-assessment questionnaire was developed jointly between WHO, FAO and OIE and circulated in the last quarter of 2016 to all countries, to collect baseline data for the set of indicators in Annex 2. The survey responses were made available online in May 2017 and used to report on country progress to the WHA, FAO, OIE and other partners. The plan is to repeat the questionnaire annually to show trends over time. The questionnaire is being reviewed and updated before it is circulated again in the last quarter of 2017.
- The format for the global AMR monitoring questionnaire (rating on a five-point scale) is consistent with the IHR joint external evaluation (JEE) tool. The JEE tool is being revised in 2017, with the intention that it should align with the AMR questionnaire, so that the JEE can contribute to validation of the global AMR monitoring survey responses. The JEE is a voluntary exercise and only envisaged on a five-yearly basis, so this will provide limited validation.
- Another option for validating country responses to the global AMR monitoring survey is to include an independent/external element in national AMR progress reviews. These reviews could be conducted annually, with independent input every two years, and form the basis for monitoring national progress and completing the self-assessment. They could be similar to the regular TB and malaria programme reviews and joint annual health sector reviews conducted by many countries. For AMR, this would need to be a multi-sector exercise that engages key stakeholders. Other forms of independent reviews could also be considered.

---

• Regarding animal health, the OIE evaluation of performance of veterinary services (OIE PVS pathway) tool will be reviewed with the support of a think tank, which will consider how AMR-related needs can be further addressed.
• The OIE sent a questionnaire on “Global action to alleviate the threat of AMR: progress and opportunities for future activities under the ‘One Health’ initiative” to Member Countries and reported to the OIE General Assembly in May 2017.

3b. Monitoring progress of the tripartite: WHO, FAO and OIE:
• WHO will monitor its own activities and performance through the WHO GAP deliverables set out in its programme budget. Six monthly reviews of progress by regional offices and work streams are planned. WHO monitoring will give particular attention to its performance and progress in countries that are most significant for the global spread of AMR.
• OIE will monitor in line with the organisation’s practices, including follow up by the AMR ad hoc Group (that meets twice a year) and relevant Commissions, to inform Member Countries on a regular basis. Also, yearly reports will be provided during each General Session.
• FAO will monitor implementation and provide feedback to Member Countries according to the organisation’s rules.
• The tripartite will report to their respective governing bodies and provide information to the Interagency Coordination Group established by the UNGA Declaration.

3c. Monitoring progress on research and development (R&D) coordination, incentive arrangements and making the economic case: AMR M&E should include progress on the following elements of GAP objective 5:
• Global progress on establishing new mechanisms and incentives for R&D for new products
• Existence and use of mechanisms that enable appropriate access to and uptake of new products
• The degree to which R&D relates to priority pathogens; and
• Progress on making the economic case for investing to address AMR.

3d. Monitoring investment in AMR responses:
• Objective 5 of the GAP includes building sustainable investment in capacity to counter AMR. This will require monitoring of funding from domestic and international sources, for country action and for R&D. Monitoring country investment is challenging because so many of the activities to prevent and control AMR are integrated with other programs and funded as part of those programs – few are additional activities that will be funded and budgeted separately. A standard approach to identifying costs of national plans, expenditures and sources of funding is proposed.
• Measurement of investment in relevant R&D should aim to assess how much is additional, stimulated by GAP and the collective response.

3e. Formative evaluation of the AMR response and how to improve it:

8 For the report see: http://www.oie.int/fileadmin/home/eng/Media_Center/docs/pdf/85SG/TT1_AMR/A_85SG_9.pdf
A formative process evaluation (or mid-term review) is proposed as part of the M&E approach. Ideally this would involve multiple partners; it could perhaps be commissioned by the Interagency Coordination Group on AMR. Timing suggested is in 2018, once implementation of NAPs can be expected to have started. The evaluation would be designed to:

- Review progress in implementing the GAP, including through multi-sectoral working at country level;
- Learn from country experience; and
- Identify how to strengthen implementation, including how to improve allocation of resources.

4. Monitoring and evaluation of outcomes and goals

Within the context of this AMR framework, monitoring of outcomes and evaluation of results and goals includes

4a. Monitoring the GAP specific outcomes in countries and in R&D

4b. Assessing general outcomes: trends in AMR rates, levels and appropriateness of antimicrobial use

4c. Modelling impact on human health and mortality and on animal health, welfare and production from infectious diseases facing AMR

4d. Assessing the availability and affordability of effective products

4e. Evaluation of why there has been progress and where to focus resources.

4a. Monitoring the five GAP specific outcomes – progress of countries and R&D:

- Countries will need to monitor progress on the specific outcomes. Annex 3 suggests possible indicators, both proxy and/or shorter term measures that could already be available in all or most countries, and outcome measures for which data may not yet be available but for which capacity can be developed. Selection of a short list of specific outcome indicators is planned following input from the consultation that will take into account what country-level data is likely to be available or easily accessible.
- Standard indicators and tools to facilitate measurement exist for some outcomes. For others, it is proposed to define standard measures and develop tools that will allow comparison across countries.
- Regional and sub-regional institutions can support monitoring of specific outcomes and collect results for regional analysis and review. Some core indicators will be reviewed at global level, by the tripartite.
- The Global AMR Surveillance System (GLASS) will monitor progress of surveillance systems towards the outcome of delivering a stronger evidence base on AMR and antimicrobial use in humans.
- OIE will monitor progress with collecting data on use in animals.
- R&D outcomes will be reflected in a growing pipeline with faster development of new products (antimicrobials, vaccines, diagnostics and alternative treatments) and, ultimately, higher numbers of approved medicines for priority infections.
4b. Assessing general outcomes: trends in AMR rates, levels and appropriateness of antimicrobial use:

- To facilitate global reporting to a wide, non-specialist audience, it would be useful to agree a limited number of standard indicators to measure trends in resistance rates and use of antimicrobials. There needs to be a consensus on which indicators to use and metrics, based on GLASS and OIE data collection for animals. Potential indicators are presented in Annex 4.
- Countries are developing their surveillance systems to monitor AMR levels and trends. In human health, the GLASS compiles global data from national systems, surveys and special studies to produce global reports on AMR levels and trends in humans. These reports will include the incidence of drug resistant infections in health facilities.
- For animals, the ATLASS will foster standardised AMR surveillance systems, enabling comparable and validated data on AMR to be collected and analysed.
- As systems develop, the data on AMR in human health should become more representative of the community alongside hospital and other health care settings, and thus include a wider range of geographic and socio-economic groups. Animal health related AMR data should also become more detailed and species-specific. To assess trends, there may need to be interpretation or adjustment for how representative the data is.
- Periodic point prevalence studies on AMR may be useful where surveillance systems are inadequate and while they are being strengthened.
- The OIE standard on harmonisation of national AMR surveillance and monitoring programmes (chapter 6.7 of the Terrestrial Animal Health Code) is under revision to include priority pathogens for monitoring for the major food producing animal species.
- Measuring the volume of antimicrobial use in human health involves collecting data on total antimicrobial sales, dispensing and/or prescribing (often referred to as consumption studies). New survey tools are being piloted in 2017 to measure antimicrobial use in hospitals and other health care settings.
- Data on use in animals are collected and analysed by the OIE, by type of use, either for total volume sold/consumption, or, where possible, by species, antimicrobial class and type of use (therapeutic or growth promotion). OIE published a first report and the second round of antimicrobial use data collection in animals is ongoing.
- Assessing appropriateness of antimicrobial use is more complex, and is likely to require studies of service quality in private and public sectors. Some countries are mainly concerned about over-use of antimicrobials, while in many countries, it is also important to address access (whether there is sufficient access to medicines when needed, which includes availability and affordability of medicines). This also applies to animal health.
- WHO will work with partners to share experience on how best to assess access and appropriate use. Work is ongoing to develop standard surveys of availability and price of medicines. Monitoring how prudently antimicrobials are used is also a challenge for animal health.
- Data will need to be collected on AMR and antimicrobial use in plant production.
- Countries can request support from WHO, FAO, OIE and other partners to strengthen their national systems, including developing laboratory capacity, animal health services, legislation, building systems for surveillance of resistance and systems to monitor antimicrobial use.
• Whilst systems for AMR surveillance and monitoring of use are being developed and implementation is getting underway, countries can review proxy and short-term indicators of progress, as suggested in annex 4.

4c. Modelling impact on human health and mortality and on animal health, welfare and production from infectious diseases facing AMR:

• Measuring the impact on health (fewer infections and lower mortality) will require data for standard tracer conditions and modelling at global level. Work is planned to estimate the burden of disease from AMR and these estimates can be used in modelling health impacts of AMR prevention and control efforts. If possible, modelling would allow for what would have happened without the GAP.
• Various organisations are supporting and working on modelling related to AMR; to maximise its usefulness to the global community, global coordination and consistency in approaches is proposed. Indicative measures are in annex 4.
• On the animal side, further analysis is required to determine how feasible it would be to measure or model effects of changes in antimicrobial use for treatment and prevention on animal health, welfare and productivity. The impact of phasing out growth promotion use of medically important antimicrobials on productivity in low- and middle-income countries, and the economic impact of amending production practices, could also be part of the exercise.
• More information on AMR from routine death and discharge data is being incorporated into the revised international classification of diseases (ICD 11). This should allow AMR information to be captured better.

4d. Assessing the availability and affordability of effective products:

• The general outcome of new diagnostic, preventive and treatment products delivered and in the pipeline, including vaccines, should be reviewed, with assessment of how far development and uptake of new products has been influenced by the GAP and related collaboration, market shaping and incentive mechanisms.
• The goal of ensuring that there continue to be effective and safe medicines and preventive products (including vaccines) available (both existing and new products) can be assessed by mapped and identifying gaps in the products available, with updating in the light of emerging resistance patterns.

4e. Evaluation of why there has been progress and where to focus resources:
An evaluation of impact and value for money (particularly efficient allocation and use of resources) after about 5 years would be desirable, to feed into review and updating of GAP. An independent assessment, jointly commissioned and funded by multiple partners is proposed, in line with United Nations Evaluation Group (UNEG) guidance. It would evaluate how appropriate the GAP is and how well implemented, including in a sample of countries.

9 In the short term, it is likely that many countries will not be able to measure some outcome indicators. In this situation, countries should seek to measure a relevant “proxy indicator” which demonstrates progress towards the intended outcome. The proxy may be an output indicator or even a process indicator.
5. Next steps

This draft M&E approach has benefitted from inputs from a range of partners and experts, including the WHO Strategic and Technical Advisory Group on AMR and experts within FAO, OIE and WHO. A meeting of experts from human and animal health and from all regions was held in June 2017. The experts provided advice on indicators (incorporated in annexes 3 and 4) and stressed the importance of being realistic about practical indicators to show progress for countries at different stages of their response to AMR. The public consultation on the M&E approach aims to gather input from the wider international community, including member states.

Definition of indicators for outcomes and goals is challenging and requires further work and consultation. Based on the results framework in Figure 3 and Annex 1, Annex 3 sets out suggestions for indicators (or types of indicators) for monitoring specific outcomes and Annex 4 addresses indicators for the general outcomes and goals. Some of these require further refinement to specify the indicator more clearly and some require studies and consultation to develop the most appropriate indicators. Data collection tools for some of the indicators are under development. The number of indicators needs to be reduced for some outcomes and the consultation will assist in selecting those that are most feasible and useful. Once the broad approach to M&E and standard indicators are defined, further work is planned on definitions and sources of indicators.

Standard measures of trends in resistance and their impact on health are probably the most challenging to agree. The intention is to have a small number of indicators that can be used to communicate trends and impact including to a non-specialist audience. However, there are multiple pathogen and drug combinations and the relevance of different pathogens varies geographically, while the transmission of resistance across pathogens suggests that the focus should not only be on specific pathogens. Following the expert meeting in June, it is proposed to select resistant pathogens/commensals as sentinel or tracer measures for global reporting (see Annex 4). It was also agreed to consider further the potential use of an aggregate measure such as a Drug Resistance Index relevant for human health.

Modelling approaches for mortality also need to be agreed, recognising limited availability of data in some cases and that not all deaths of people who have a resistant infection are caused by the resistance. The analysis needs to consider the interaction between prevention of infection and AMR — if infections are prevented, there should be less use of antimicrobials, which would slow down the emergence and spread of AMR; while lower prevalence may mask the effect of AMR on mortality rates. Increasing the evidence on the impact of resistance on clinical outcomes is important as the basis for modelling health impacts. WHO is starting a review of approaches to modelling the health burden of AMR and can take a role in establishing coherent approaches across different modelling exercises.

---

10 For example, the international community has agreed that GLASS should gather data on 8 pathogens with multiple antibacterial classes for 7 of them to monitor resistance in humans. For animals, there are multiple species as well as combinations to monitor (OIE’s report on use identifies more than 13 food-producing species and production settings.

Some countries may seek support with developing their M&E plans. This can include establishing a community of practice to share experience with implementing M&E of national AMR plans. As noted above, there is also work planned to develop a ‘menu’ of output indicators that can be used for NAPs.

The High Level Meeting at UNGA defined a new Interagency Coordination Group on AMR. The Group has been established, and held a first meeting in May 2017. The tripartite is proceeding with technical work on defining indicators and will present this monitoring framework and indicators to the Group for consideration.
### Annex 1: Summary of results chain for GAP and the response to AMR

Links to Figure 3.

<table>
<thead>
<tr>
<th>Result chain level</th>
<th>Results statement</th>
</tr>
</thead>
</table>
| **Goals**          | Overarching goal: Lower impact from infectious diseases on human and animal health.  
|                    | GAP goal: Continued ability to treat and prevent infectious diseases with effective and safe medicines. |
| **General outcomes** | A: Slower development of resistance (reduce emergence and spread of resistance or reduce levels).  
|                    | B: More appropriate use of antimicrobials, with increased access when needed and less inappropriate use.  
|                    | C: New medicines, diagnostics, vaccines and other interventions related to priority infections are available and affordable. |
| **Specific outcomes** | 1: Improved awareness of AMR & behaviour change among policy makers, farmers, veterinary and human health workers, food industry and the general public.  
|                    | 2: Strengthened knowledge and evidence base is used for policy and practice decisions.  
|                    | 3: Effective prevention reduces infection incidence in health facilities, farms & communities, and reduces environmental contamination.  
|                    | 4: Optimized use of antimicrobials in human and animal health; animal use for growth promotion phased out.  
|                    | 5: Increased R&D on new medicines, diagnostics, vaccines & other interventions related to priority pathogens. |
| **Outputs**        | 1.1 Awareness and understanding increased of AMR risks and response in human health.  
|                    | 1.2 Awareness and understanding of AMR risks and response in animal health, plants and food production.  
|                    | 1.3 Training and professional education on AMR in the human health sector.  
|                    | 1.4 Training and professional education on AMR in the veterinary sector.  
|                    | 1.5. Strengthened veterinary services.  
|                    | 2.1 Monitoring system for consumption & appropriate use of antimicrobials in human health.  
|                    | 2.2 Monitoring system for antimicrobial use in animals and plant production.  
|                    | 2.3 Surveillance system for AMR in humans.  
|                    | 2.4 Surveillance system for AMR in animals and foods.  
|                    | 2.5 Research on resistance and how to improve antimicrobial use conducted and published.  
|                    | 3.1 Infection Prevention and Control in human health care.  
|                    | 3.2 Good animal health and management practices and good hygiene to prevent infections and reduce the use of antimicrobials in animals and AMR transmission in food production.  
|                    | 3.3 Scaled up water supplies, sanitation, hygiene and immunisation to reduce spread of infections in communities.  
|                    | 4.1 Optimising antimicrobial use & regulation in human health.  
|                    | 4.2 Optimising antimicrobial use & regulation in animal and plant production.  
|                    | 4.3 Legislation and/or regulations to prevent contamination of the environment with antimicrobials.  
|                    | 5.1 Estimates of funding needs and economic case for investment in AMR responses.  
|                    | 5.2 Coordinated efforts, with priorities defined and mechanisms established to incentivise relevant R&D.  
|                    | 5.3. Increased investment in R&D to address AMR and prevent infection. |
### Annex 2: Global level monitoring of outputs

This table sets out the measures of country progress with implementation of strategies to address AMR, based on the global AMR monitoring survey in 2016/17 with some updating. This survey is under review before the next round of data collection late in 2017 so the indicators may be updated further. The survey asks countries to self-assess against key aspects of the GAP. In order to keep the length of the survey manageable, some elements are not included.

<table>
<thead>
<tr>
<th>Specific outcome</th>
<th>Outputs defined in results framework</th>
<th>Output indicators for global-level tripartite monitoring (based on country questionnaire)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. Improved awareness of AMR &amp; behaviour change among policy makers, farmers, veterinary and human health workers, food industry and the general public.</td>
<td>1.1 Awareness and understanding increased of AMR risks and response in human health.</td>
<td>Distribution of countries across the scale from A to E (for all countries/by region/high population countries etc.):&lt;br&gt; A. % of countries with no significant awareness-raising activities on AMR.&lt;br&gt; B. % of countries with some activities in parts of the country to raise awareness about antibiotic resistance and actions to address it.&lt;br&gt; C. % of countries with nationwide antibiotic awareness campaign targeting the general public, with government involvement.&lt;br&gt;D. % of countries with nationwide, government-supported antibiotic awareness campaign targeting specific groups (e.g. doctors, pharmacists, nurses, drug sellers).&lt;br&gt; E. % of countries with focused, national scale activities to change behaviour in target groups in human health, both public and private sectors; and monitoring of awareness and behaviour change in last 5 years.</td>
</tr>
<tr>
<td></td>
<td>1.2 Awareness and understanding of AMR risks and response in animal health, plants and food production.</td>
<td>Distribution of countries across the scale from A to E, (for all countries/by region/high animal producing countries etc.) i.e.:&lt;br&gt; A. % of countries with no significant awareness-raising activities on risks of antibiotic resistance for animal health and risks of transmission of resistant pathogens through the food chain.&lt;br&gt; B. % of countries with some activities in parts of the country to raise awareness about antimicrobial resistance and actions to address it.&lt;br&gt; C. % of countries with nationwide, antimicrobial awareness campaign targeting food producers and farmers, with government involvement.&lt;br&gt; D. % of countries with nationwide, government-supported antimicrobial awareness campaign targeting specific groups (e.g. veterinarians, veterinary para-professionals, farmers, pharmaceutical agents).&lt;br&gt; E. % of countries with focused, national scale activities to change behaviour in target groups in animal health, animal husbandry and in the food chain, in both public and private sectors; and monitoring of awareness and behaviour change in last 5 years.</td>
</tr>
<tr>
<td></td>
<td>1.3 Training and professional education on AMR</td>
<td>Distribution of countries across the scale from A to E, i.e.:&lt;br&gt; A. % of countries with no training for health workers on AMR.&lt;br&gt; B. % of countries with ad hoc training courses in some health-related disciplines.&lt;br&gt; C. % of countries where AMR is covered in some pre-service training and/or some special courses for health workers.</td>
</tr>
<tr>
<td>Specific outcome</td>
<td>Outputs defined in results framework</td>
<td>Output indicators for global-level tripartite monitoring (based on country questionnaire)</td>
</tr>
<tr>
<td>---------------------------------------------------------------------------------</td>
<td>-------------------------------------------------------------------------------------------------------</td>
<td>------------------------------------------------------------------------------------------------------------------------------------------------------------</td>
</tr>
</tbody>
</table>
| 1.4 Training and professional education on AMR in the veterinary sector.         | D. % of countries where continuing professional development (CPD) opportunities are available nationwide for health workers on AMR and implications for antimicrobial use & infection prevention.  
E. % of countries where AMR is systematically incorporated in pre-service training curricula for all relevant health cadres. Regular continuing professional development on AMR reaches relevant groups for human health nationwide, in public and private sectors. | Distribution of countries across the scale from A to E, i.e.:  
A. % of countries with no training of veterinary workforce on AMR.  
B. % of countries with ad hoc training courses on AMR available.  
C. % of countries with regular participation in training opportunities on AMR.  
D. % of countries where training opportunities are available nationwide for public and private sector veterinarians, veterinary para-professionals and animal health workforce on mechanisms leading to AMR, regulations and best practices for antimicrobial use.  
E. % of countries with AMR incorporated in core veterinary education and continuing professional development for veterinarians, veterinary para-professionals and others involved in animal health and agriculture. |
| 1.5 Strengthened veterinary services.                                            | Distribution of countries across the scale from A to E, i.e.:  
A. % of countries with no systematic approach at national level to strengthening Veterinary Services.  
B. % of countries where veterinary services assessed and plans developed to improve capacity, through a structured approach such as OIE Performance of Veterinary Services (PVS) Evaluation and PVS Gap Analysis missions.  
C. % of countries with implementation of plan to strengthen capacity gaps in Veterinary Services underway.  
D. % of countries with monitoring of Veterinary Services performance carried out regularly, e.g. through PVS Evaluation Follow Up missions.  
E. % of countries with documented evidence of strong capacity in compliance with OIE standards on the quality of Veterinary Services. |  

2. Strengthened knowledge and evidence base is used for policy and practice decisions  
2.1 Monitoring system for consumption & appropriate use of antimicrobials in human health. | Distribution of countries across the scale from A to E, i.e.:  
A. % of countries with no national plan or system for monitoring use of antimicrobials.  
B. % of countries with a system designed for surveillance of antimicrobial use, that includes monitoring national level sales or consumption of antibiotics and rational use of antibiotics in health services.  
C. % of countries where total sales of antimicrobials are monitored at national level and/or some monitoring of antibiotic use at sub-national level.  
D. % of countries where prescribing practices and antibiotic use are monitored in a national sample of healthcare settings.  
E. % of countries where, on a regular basis (every year/two years), data is collected and reported on:  
a) Antimicrobial sales or consumption at national level for human use; and  
b) Antibiotic prescribing and appropriate use, in a representative sample of health facilities, public and private. |  

Draft AMR M&E Approach Paper
<table>
<thead>
<tr>
<th>Specific outcome</th>
<th>Outputs defined in results framework</th>
<th>Output indicators for global-level tripartite monitoring (based on country questionnaire)</th>
</tr>
</thead>
</table>
| 2.2 Monitoring system for antimicrobial use in animals and plant production. | | Distribution of countries across the scale from A to E, i.e.:  
A. % of countries with no national plan or system for monitoring use of antimicrobials in animal or plant production.  
B. % of countries with a Plan agreed for monitoring quantities of antimicrobials used in animals, based on OIE standards.  
C. % of countries with implementation of plans to monitor sales, consumption and type of use (therapeutic or growth promotion).  
D. % of countries with data collected and reported on national sales or consumption of antimicrobials for animal production.  
E. % of countries where, on a regular basis, data is collected and reported on:  
   a) Antimicrobial sales or consumption at national level for animal production by type of use (therapeutic or growth promotion).  
   b) Appropriate use of antimicrobials, under veterinary supervision, in a sample of farms, for at least 2 animal species.  
   c) Antimicrobial sales or consumption for plant production.  
   d) Participation in OIE data collection on antimicrobials sold for/used in animals by species, antimicrobial class and type of use. |
| 2.3 National surveillance system for antimicrobial resistance (AMR) in humans. | | Distribution of countries across the scale from A to E, i.e.:  
A. % of countries with no capacity for generating data and reporting on antibiotic resistance (antibiotic susceptibility testing and accompanying clinical and epidemiological data collection).  
B. % of countries where AMR data is collated locally for common bacteria, but may not use a standardized approach and lacks national coordination and/or quality management.  
C. % of countries where national AMR surveillance activities are in place for common bacterial pathogens that link patient information with susceptibility testing, with a national reference laboratory that participates in external quality assurance.  
D. % of countries where there is a functioning national AMR surveillance system covering antibiotics in hospitals and outpatient clinics, with external quality assurance, and a national coordinating centre producing reports on resistance levels.  
E. % of countries where the national AMR surveillance system integrates surveillance of AMR in human and animal health and agriculture, and generates regular reports. |
| 2.4 National surveillance system for antimicrobial resistance (AMR) | | Distribution of countries across the scale from A to E, i.e.:  
A. % of countries with no national plan or system for monitoring AMR in animals, food and agricultural production.  
B. % of countries where AMR data is collected locally but may not use a standardised approach and lacks national coordination and/or quality assurance. Priority pathogens have been identified for surveillance.  
C. % of countries with studies available on levels of resistance in at least 2 pathogens relevant for animals. |
<table>
<thead>
<tr>
<th>Specific outcome</th>
<th>Outputs defined in results framework</th>
<th>Output indicators for global-level tripartite monitoring (based on country questionnaire)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>D. % of countries with national system of surveillance of AMR established for relevant animal pathogens which follows quality assurance processes in line with intergovernmental standards. Laboratories that report for AMR surveillance follow quality assurance processes.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>E. % of countries with data collected and reported on a regular basis on AMR in relevant pathogens for animals and in food.</td>
</tr>
<tr>
<td>2.5 Research on AMR and how to improve AM use conducted and published.</td>
<td>[Not monitored at global level]</td>
<td></td>
</tr>
<tr>
<td>3. Effective prevention reduces infection incidence in health facilities, farms &amp; communities, and reduces environmental contamination</td>
<td>3.1 Infection Prevention and Control (IPC) in human health care.</td>
<td>Distribution of countries across the scale from A to E, i.e.:</td>
</tr>
<tr>
<td></td>
<td></td>
<td>A. % of countries where no national IPC policy or plan is available.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>B. % of countries where a national IPC policy or operational plan is available, with standard operating procedures (SOPs), guidelines and protocols available to all hospitals.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>C. % of countries where national guidelines for health care IPC are available and disseminated. Selected health care facilities are implementing the guidelines, with monitoring and feedback in place. All referral hospitals have WASH facilities that are functional, in line with national standards.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>D. % of countries with IPC plans and guidelines implemented nationwide in public and private sectors. All health care facilities have a functional built environment (including water and sanitation), and necessary materials and equipment to perform IPC, per national standards.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>E. % of countries where IPC is in place and functioning at national and health facility levels. Compliance and effectiveness regularly evaluated and published. Plans and guidance are updated in response to monitoring.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>3.2 Good animal health and management practices and good hygiene to prevent infections and reduce the use of AMs in animals and AMR</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Distribution of countries across the scale from A to E, i.e.:</td>
</tr>
<tr>
<td></td>
<td></td>
<td>A. % of countries with no systematic efforts to improve infection prevention in the animal and food production sectors related to reducing use of antimicrobials.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>B. % of countries with plan agreed to promote farm hygiene, increase vaccination, biosecurity and appropriate handling of sick animals to prevent transmission of resistant bacteria to other animals and humans.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>C. % of countries with an implementation of plan for infection prevention in food producing animals for some species, types of farms or geographical areas based on intergovernmental standards. Practical guidance developed and disseminated.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>D. % of countries with nationwide implementation of plan for infection prevention in animals in public and private sectors and in collaboration with veterinarians.</td>
</tr>
<tr>
<td>Specific outcome</td>
<td>Outputs defined in results framework</td>
<td>Output indicators for global-level tripartite monitoring (based on country questionnaire)</td>
</tr>
<tr>
<td>------------------</td>
<td>--------------------------------------</td>
<td>------------------------------------------------------------------------------------------------</td>
</tr>
<tr>
<td></td>
<td>transmission in food production.</td>
<td>E. % of countries with monitoring of progress on infection prevention relevant to reducing use of antimicrobials in animals, veterinary practices and food chains, with updating of plans and guidance in response to findings.</td>
</tr>
</tbody>
</table>
| 3.3 Scaled up water supplies, sanitation, hygiene and immunisation to reduce spread of infections in communities. | i. Average immunization coverage rates in most recent year for which data is:  
   a) Average immunisation coverage rate (in %) of *pneumococcus vaccine*.  
   b) Average immunisation coverage rate (in %) of *Haemophilus influenza type b (Hib) vaccine*.  
   ii. Distribution of countries by proportion (%) of health care facilities with:  
   a) Basic water supplies.  
   b) Basic hand hygiene facilities. |
| 4. Optimized use of antimicrobials in human and animal health. | 4.1 Optimising antimicrobial use & regulation in human health. | Distribution of countries across the scale from A to E, i.e.:  
A. % of countries with *no/weak national policy & regulations for appropriate use, availability and quality of antimicrobials*.  
B. % of countries with a *national policy for antimicrobial governance and regulation developed, that addresses appropriate use, availability and quality of antibiotics in the community and in health care settings*.  
C. % of countries with *practices to assure appropriate antimicrobial use being implemented in some healthcare facilities and guidelines for appropriate use of antimicrobials available*. Legislation and regulations approved on import, marketing authorisation, production, and use of antimicrobials.  
D. % of countries where *practices to enable appropriate use are implemented in most health facilities nationwide, for all antibiotics*. Relevant legislation has been reviewed for coherence; gaps/overlaps/ inconsistencies have been identified.  
E. % of countries where relevant legislation has been revised and a coherent framework is in place and fully functional, so that only licensed and quality proved drugs are in use. Monitoring and surveillance results are used to inform action and to update treatment guidelines and essential medicines lists. |
|                  | 4.2 Optimising antimicrobial use & regulation in animal and plant production. | Distribution of countries across the scale from A to E: i.e.:  
A. % of countries with *no national policy or legislation regarding the quality and efficacy of antimicrobials and their use in animals and plants*.  
B. % of countries with a *national policy for antimicrobial governance and regulation developed, that addresses responsible and prudent use, availability and quality of antimicrobials for animal use*.  
C. % of countries with *legislation and regulations approved on import, marketing authorisation, production, distribution and prudent use of high-quality veterinary medicinal products including antimicrobials, based on international standards. Guidelines for appropriate use of antimicrobials are available*.  
D. % of countries with *practices widely implemented on responsible and prudent use in animals and plants in line with Codex and OIE standards*. Use of antimicrobials for animal growth promotion has been phased out. |
<table>
<thead>
<tr>
<th>Specific outcome</th>
<th>Outputs defined in results framework</th>
<th>Output indicators for global-level tripartite monitoring (based on country questionnaire)</th>
</tr>
</thead>
<tbody>
<tr>
<td>4.3 Legislation and/or regulations to prevent contamination of the environment with antimicrobials.</td>
<td>Distribution of countries across the scale from A to E, i.e.:</td>
<td>E. % of countries where relevant legislation has been revised and a coherent framework is in place and fully functional, so that only licensed and quality proved drugs are in use. Antimicrobials given to animals are only used to control or treat infectious diseases, under veterinary supervision.</td>
</tr>
<tr>
<td>5. Increased R&amp;D on new medicines, diagnostics, vaccines &amp; other interventions related to priority pathogens.</td>
<td>Estimates of funding needs and economic case for investment in AMR responses.</td>
<td>[Not included in country questionnaire.] Global estimates of funding gaps.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>[Data collection for these indicators will come from various R&amp;D monitoring sources, collated at global level]. Priority pathogens identified. New mechanisms in place to incentivise R&amp;D and increase access.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>[Data collection for these indicators will come from various R&amp;D monitoring sources, collated at global level]. Commitments and expenditure on R&amp;D for priority pathogens.</td>
</tr>
</tbody>
</table>

Proposed indicators suggested here for specific outcomes 1 to 5 (corresponding to GAP strategic objectives 1 to 5) are linked to the results framework and recommendations of the expert meeting. The indicators can be used at national level and could also be collated at global level. The list is longer than desirable, and the tripartite intends to reduce the number of indicators under each specific outcome. The consultation is seeking inputs on the relevance, usefulness and feasibility of the indicators as a basis to select the most useful indicators.

**Short term or proxy indicators** have been proposed recognising that many countries will not be able to measure progress on outcomes in the short term, either because there are not yet systems for data collection and/or because there will be little progress to measure in that timeline. The short term or proxy indicators are intended to show whether there is progress towards measuring and achieving the outcomes. The intention is that the majority of countries should be able to report their progress on these within the next five years, including to regional and global levels.

**Outcome indicators** should be collected and reported when possible and available. Those countries that have the capacity to do so are expected to monitor outcomes. It is recognised that some countries will take years to build up systems for collecting and analysing representative data and to make progress on achieving the outcomes; however, it is envisaged that the majority of countries will be able to collect and report outcome data within the next 10 years.

**Blue shading** denotes indicators specific to animal, plant production and environment sectors. No shading (white background) includes indicators for human health and in some cases, indicators that are relevant across sectors.
<table>
<thead>
<tr>
<th>Specific outcome</th>
<th>Short term/proxy indicators for outcomes (most countries should be able to report within 5 years)</th>
<th>Outcome indicators (some are already collected; expect most countries to be able to report within 10 years)</th>
</tr>
</thead>
</table>
| Improved awareness of AMR & behaviour change among policy makers, farmers, veterinary and human health workers, food industry and the general public. | **1.** Government-supported antimicrobial awareness campaign(s) undertaken, by target group.  
**1.2:** Country has a One Health AMR communications strategy in place.  
**1.3:** Tailored national communications materials aimed at farmers/veterinarians/agricultural workers easily available in official language.  
**1.4:** % of health education institutions that have incorporated AMR educational modules in their core curricula /in Day 1 competencies.  
**1.5:** Number of conferences and/or education sessions (trainings) on AMR/year given to target actors (farmers/veterinarians/agricultural workers and/or number of target actors trained/year.  
**1.6:** Veterinary and/or animal health worker governing body exists within country.  
**1.7:** Specific training on AMR included in veterinary and animal health/veterinary paraprofessional training.  
**1.8:** Whether country has in the last 5 years had a) Performance of Veterinary Services (PVS) evaluation b) PVS gap analysis c) PVS follow up d) another systematic process to evaluate and strengthen vet services. | **Awareness levels on AMR, understanding/attitudes and behaviours by target group.**  
Suggested:  
**1.9:** % of public who know use of antibiotics causes resistance.  
**1.10:** % who know inappropriate to use antibiotics for common cold or viruses.  
**1.11:** % of actors (e.g. policy-makers, veterinarians, animal health workers, farmers, food processing workers) that have knowledge (TBD) about AMR.  
**1.12:** Knowledge and attitudes of health workers on AMR and implications for antimicrobial use and infection prevention (detailed questions TBD).  
**Trends in behaviour for target groups:**  
**General population**  
**1.13:** % of antibiotic use in community based on a prescription.  
**1.14:** Use of left over antibiotics (in community).  
**1.15:** Use of antibiotics for a cold or flu.  
**Behaviour of farmers, veterinarians, other animal health workers:**  
**1.16:** % of veterinary/plant antimicrobial sales that are critically important antimicrobials.  
**1.17:** % of veterinary AMs authorised/used for non-therapeutic purposes (e.g. for growth promotion).  
**1.18:** AMs sold/used in plant production.  
**Behaviour of health workers**  
**1.19:** Hand hygiene performed by health professional during last encounter.  
**1.20:** Prescribing—average number of antibiotic prescriptions per 1000 inhabitants per year; proportion prescribed a restricted antibiotic.  
**1.21:** Use of diagnostics.  
**1.22:** Use of antimicrobial susceptibility tests.  
**Education and training outcomes - metrics to be refined, such as:** |

---


13 These would measure changes in behaviour for different groups: the regulators (what is authorised), professionals (prescription practices), and farmers (actual use).
<table>
<thead>
<tr>
<th>Specific outcome</th>
<th>Short term/proxy indicators for outcomes (most countries should be able to report within 5 years)</th>
<th>Outcome indicators (some are already collected; expect most countries to be able to report within 10 years)</th>
</tr>
</thead>
</table>
| **2. Strengthened knowledge and evidence base is used for policy and practice decisions.** | **2.1:** Country collects national data on total sales or consumption of antibiotics for human use.  
**2.2:** Country has a system for active feedback to prescribers on their prescribing.  
**2.3:** Number/proportion of production sectors collecting data on veterinary/plant AM sales/use.  
**2.4:** Country makes data on antimicrobial sales or use in animals available to national stakeholders.  
**2.5:** Country reports data on antimicrobial sales or use in animals to OIE database.  
**2.6:** National reference laboratory for AMR surveillance in human health designated and participating in an external quality assurance scheme [GLASS indicator].  
**2.7:** National AMR surveillance programme organizes and runs external quality assurance for all laboratories participating in GLASS, for bacterial identification and antimicrobial susceptibility testing [GLASS indicator].  
**2.8:** Country has veterinary public health lab network with capacity to conduct standardized, repeatable, antimicrobial susceptibility testing for key isolates (veterinary/food borne pathogens and commensals) based on recognised international standards.  
**2.9:** Country has national (or access to regional) reference laboratory for veterinary public health.  
**2.10:** Country has implemented a national system of surveillance for one or more key isolates from animals/plants/environment.  
**2.11:** Country collects non-human health AMR surveillance data including prevalence of ESBL commensal *E. coli* in healthy animals in 2 key food producing species. | **2.15:** Country regularly reports AM use data in animals (sales or supply or actual use), broken down by species, sector and administration route, to OIE database.  
**2.16:** Country regularly reports use data in non-human/animal health sectors, e.g. plant production.  
**2.17:** Number of sectors that have amended food production management practices to minimize development or transmission of AMR.  
**2.18:** Evidence that relevant body has reviewed surveillance data and adjusted recommendations (e.g. essential medicines list, treatment guidelines and/or prevention guidelines), in light of AMR data.  
**2.19:** % of hospitals where AMR data is provided on regular basis to local prescribing hospital based physicians on regional or local level.  
**2.20:** National body in charge of national strategy to contain AMR receives information on AMR rates and progress of implementation of surveillance systems at least once per year and discusses implications for national strategy.  
**2.21:** Country has reviewed existing legislation and developed a framework for revision of legislation to achieve effective system of regulation of manufacture, distribution, supply and administration of medical and non-medical AMs.  
**2.22:** Animal health, plant health and human health have integrated surveillance systems.  
**2.23:** Integrated analysis and reporting of AMR within country. |
<table>
<thead>
<tr>
<th>Specific outcome</th>
<th>Short term/proxy indicators for outcomes</th>
<th>Outcome indicators</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>(most countries should be able to report within 5 years)</td>
<td>(some are already collected; expect most countries to be able to report within 10 years.)</td>
</tr>
<tr>
<td>2.12:</td>
<td>Country has published and reported AMR surveillance data.</td>
<td></td>
</tr>
<tr>
<td>2.13:</td>
<td>Country has database for collection and reporting of resistance data on non-human-health isolates.</td>
<td></td>
</tr>
<tr>
<td>2.14:</td>
<td>Availability of antimicrobial susceptibility tests in plant and animal health, e.g. tests available for specified pathogen and animal species for specific presentation and class of antimicrobial.</td>
<td></td>
</tr>
<tr>
<td>3.</td>
<td><strong>Effective prevention reduces infection incidence in health facilities, farms &amp; communities, and reduces environmental contamination.</strong></td>
<td></td>
</tr>
<tr>
<td>3.1:</td>
<td>National Infection prevention and control (IPC) program is in place.</td>
<td></td>
</tr>
<tr>
<td>3.2:</td>
<td>% of acute health care facilities with IPC program in place.</td>
<td></td>
</tr>
<tr>
<td>3.3:</td>
<td>% of health facilities with at least basic water supply*.</td>
<td></td>
</tr>
<tr>
<td>3.4:</td>
<td>% of health facilities with at least basic sanitation*.</td>
<td></td>
</tr>
<tr>
<td>3.5:</td>
<td>% of health facilities with at least basic hand hygiene*. <em>(basic as defined in WASH in health care facility standards or national standards)</em></td>
<td></td>
</tr>
<tr>
<td>3.6:</td>
<td>% of health facilities with a functional built environment (including water and sanitation), and necessary materials and equipment to perform IPC, as per national standards.</td>
<td></td>
</tr>
<tr>
<td>3.7:</td>
<td>Number of infection control programmes OR % of diseases (in key food producing animal species) that are covered by an infection control programme.</td>
<td></td>
</tr>
<tr>
<td>3.8:</td>
<td>Number of sectors within country with guidance available on good agricultural practices in official or local language.</td>
<td></td>
</tr>
<tr>
<td>3.9:</td>
<td>Level of access to veterinary advice and care within country (e.g. number of qualified vets to animal population).</td>
<td></td>
</tr>
<tr>
<td>3.10:</td>
<td>Country legislates minimum standards of husbandry/housing/ biosecurity for food animal production, e.g. in accordance with OIE and Codex standards and guidelines.</td>
<td></td>
</tr>
<tr>
<td>3.11:</td>
<td>Country legislates regulation of production/access to medicated feed.</td>
<td></td>
</tr>
<tr>
<td>3.12:</td>
<td>Country has adopted and is compliant with OIE and Codex standards and guidelines on infection prevention/food safety.</td>
<td></td>
</tr>
<tr>
<td>3.16:</td>
<td>% of health facilities monitoring hand hygiene compliance of health workers according to the WHO direct observation method or similar method.</td>
<td></td>
</tr>
<tr>
<td>3.17:</td>
<td>Surgical site infection incidence rate1 including % resistant (in accordance with GLASS) when feasible.</td>
<td></td>
</tr>
<tr>
<td>3.18:</td>
<td>Rate of readmissions due to surgical site infection.</td>
<td></td>
</tr>
<tr>
<td>3.19:</td>
<td>Bloodstream Infections per 1000 patient days (inpatients, admitted &gt;48 hrs).</td>
<td></td>
</tr>
<tr>
<td>3.20:</td>
<td>Rate of neonatal sepsis including % of those caused by resistant bacteria (in accordance with GLASS) or new-borns with suspected severe bacterial infection who receive appropriate antibiotic therapy.</td>
<td></td>
</tr>
<tr>
<td>3.21:</td>
<td><em>Clostridium difficile</em> incidence in hospitals and community.</td>
<td></td>
</tr>
<tr>
<td>3.22:</td>
<td>% of commercial farms that have implemented a biosecurity programme.</td>
<td></td>
</tr>
<tr>
<td>3.23:</td>
<td>% of farms surveyed compliant with standards of responsible and prudent antimicrobial use in animals, including good husbandry and hygiene practices.</td>
<td></td>
</tr>
<tr>
<td>3.24:</td>
<td>% of population using safely managed drinking water services (SDG6 indicator).</td>
<td></td>
</tr>
<tr>
<td>3.25:</td>
<td>% of population using safely managed sanitation services, including a hand-washing facility with soap and water (SDG6 indicator).</td>
<td></td>
</tr>
<tr>
<td>3.26:</td>
<td>Coverage with pneumococcal conjugate vaccine (3 doses), rotavirus, measles and Hib vaccines.</td>
<td></td>
</tr>
<tr>
<td>3.27:</td>
<td>% of children with full immunisation coverage according to national immunization guidelines.</td>
<td></td>
</tr>
<tr>
<td>3.28:</td>
<td>Level of vaccine coverage within animal populations nationally for priority diseases.</td>
<td></td>
</tr>
<tr>
<td>Specific outcome</td>
<td>Short term/proxy indicators for outcomes (most countries should be able to report within 5 years)</td>
<td>Outcome indicators (some are already collected; expect most countries to be able to report within 10 years.)</td>
</tr>
<tr>
<td>------------------</td>
<td>-----------------------------------------------------------------------------------------------------------------</td>
<td>-------------------------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>3.13: Country includes relevant vaccines in their human immunisation program: Hib, pneumococcal conjugate vaccine, rotavirus, measles, flu.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>3.14: Country has determined priority animal diseases for which vaccination would reduce the use of antimicrobials.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>3.15: Proportion of these priority animal diseases for which vaccine is available in country.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>4.1: Country has AM guidelines and regulates the prescription and sale of AMs for human use.</td>
<td>4.17: % of prescriptions that are supported by a clinical diagnosis.</td>
<td></td>
</tr>
<tr>
<td>4.2: Country has a national target for AM use per capita in human health.</td>
<td>4.18: % of empirical prescribing of antibiotics in line with guidelines or hospital prescribing policy.</td>
<td></td>
</tr>
<tr>
<td>4.3: Country has targets for antibiotic prescribing, with systems or incentives to encourage appropriate behaviours.</td>
<td>4.19: Watch and Reserve antibiotic use compared to Access antibiotics or ratio of sales of Watch to Reserve antibiotics.</td>
<td></td>
</tr>
<tr>
<td>4.4: Country has access/watch/reserve AM categories in national guidelines or essential medicine list for human health care.</td>
<td>4.20: National prescribing guidelines updated to reflect local and epidemiological antimicrobial susceptibility data (for human and animal health).</td>
<td></td>
</tr>
<tr>
<td>4.5: Country conducts aftermarket quality assurance testing on AMs on sale.</td>
<td>4.21: Compliance with surgical prophylaxis guidelines.</td>
<td></td>
</tr>
<tr>
<td>4.6: Country has regulatory framework for veterinary medicines in accordance with OIE terrestrial and aquatic codes and CODEX texts on food borne AMR.</td>
<td>4.22: % of Sexually Transmitted Infection prescriptions in line with guidelines.</td>
<td></td>
</tr>
<tr>
<td>4.7: Country has publicly accessible list of all AM products authorised for national use.</td>
<td>4.23: % of diarrhoea treatment in line with guidelines.</td>
<td></td>
</tr>
<tr>
<td>4.8: Country regulates use of antimicrobials in plant production.</td>
<td>4.24: % of drugs available that are licensed for sale in country.</td>
<td></td>
</tr>
<tr>
<td>4.9: Country does not permit use of medically Important antimicrobials for growth promotion.</td>
<td>4.25: Risk based testing of drug quality/ presence of a quality process for AMs (to be further defined).</td>
<td></td>
</tr>
<tr>
<td>4.10: Country has recommendations to restrict use of specific antimicrobial classes listed as Critically Important for humans and animals.</td>
<td>4.26: % of tracer antibiotics with enough active ingredient.</td>
<td></td>
</tr>
<tr>
<td>4.11: Country has national or regional level veterinary prescribing guidelines in official language available for priority food producing species, being used and regularly updated.</td>
<td>4.27: % of antimicrobials in local market that are unauthorized and sub-standard antimicrobials.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>4.28: Availability of “access” drugs (i.e. not watch or reserve) in pharmacies and health facilities.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>4.29: Drug shortages experienced in last 6 months at national level.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>4.30: Stock outs (non-availability) of specified antibiotics at intermediate levels of the medicines supply chain (central warehouse to regional or district medical stores and distributors).</td>
<td></td>
</tr>
<tr>
<td></td>
<td>4.31: % of AM use in animals based on prescriptions with veterinary oversight.</td>
<td></td>
</tr>
</tbody>
</table>

\[14\text{ i.e. diseases with greatest impact on animal health and production in key food producing species that are relevant regarding the use of antimicrobials in animals}\]
<table>
<thead>
<tr>
<th>Specific outcome</th>
<th>Short term/proxy indicators for outcomes (most countries should be able to report within 5 years)</th>
<th>Outcome indicators (some are already collected; expect most countries to be able to report within 10 years).</th>
</tr>
</thead>
<tbody>
<tr>
<td>4.12</td>
<td>Country instigates programme of AM residue testing in animal and non-animal origin foodstuffs.</td>
<td>4.32: Antimicrobial susceptibility testing is being done appropriately/when needed.</td>
</tr>
<tr>
<td>4.13</td>
<td>Country implements regulatory measures on residues based on Codex standards and guidelines.</td>
<td>4.33: Proportion of wastewater safely treated (SDG6 indicator).</td>
</tr>
<tr>
<td>4.14</td>
<td>Maximum residue levels (MRLs) are recognized; withdrawal periods are required to be based on these MRLs.</td>
<td>4.34: Availability of antibiotics in veterinary outlets in public and private sectors, compared with treatment guidelines.</td>
</tr>
<tr>
<td>4.15</td>
<td>Authorised Withdrawal Periods are legally required to be displayed on antimicrobial packaging.</td>
<td></td>
</tr>
<tr>
<td>4.16</td>
<td>Country has regulations for discharge of antimicrobials into the environment.</td>
<td></td>
</tr>
<tr>
<td>5.1</td>
<td>National estimates available of investment needs and funding gaps.</td>
<td>5.8: Global R&amp;D pipeline: Numbers and targeted infections of antimicrobial medicines, alternative treatments, vaccines and diagnostics in the R&amp;D pipeline (assessed against baseline and research priorities).</td>
</tr>
<tr>
<td>5.2</td>
<td>Proportion of NAP activities and budget implemented.</td>
<td></td>
</tr>
<tr>
<td>5.3</td>
<td>New mechanisms in place to incentivise R&amp;D (e.g. prizes, advance market commitments, pilots for delinking costs of product development from sales income).</td>
<td></td>
</tr>
<tr>
<td>5.4</td>
<td>Mechanisms in place to facilitate equitable access to existing and new products.</td>
<td></td>
</tr>
<tr>
<td>5.5</td>
<td>Global Framework for Development and Stewardship to combat AMR agreed.</td>
<td></td>
</tr>
<tr>
<td>5.6</td>
<td>Commitments and expenditure on R&amp;D for priority pathogens (new products, new drug combinations, diagnostics, vaccines, etc.).</td>
<td></td>
</tr>
<tr>
<td>5.7</td>
<td>Level of funding raised for the Global Antibiotic Research and Development Facility.</td>
<td></td>
</tr>
</tbody>
</table>

---

**Annex 4: Proposed General Outcome and Goal Indicators**

This table identifies proposed standard (core) indicators related to the general outcomes and goals defined in the results framework. The indicators are shown for the global level; most will rely on reporting from countries to compile the results. In the short term, some countries will not have data available for all the indicators, therefore proxy measures will be used (see short term/proxy measures below and in annex 3). As country monitoring and surveillance systems develop, the number of countries able to provide data on outcomes will increase.

Blue shading denotes indicators specific to the animal, plant production and environment sectors.

<table>
<thead>
<tr>
<th>Result level</th>
<th>Proposed indicators: Global level</th>
</tr>
</thead>
</table>
| **General outcome A: slower development of resistance.** | **Patterns and trends in resistance in human health** in the following, analysed by region; for large population countries; for countries which have data available:  
A.1: Carbapenem resistant enterobacteriaceae  
A.2: Methicillin-resistant *Staphylococcus aureus* (MRSA)  
A.3: Extended spectrum beta lactamase (ESBL) in *E. coli*  
A.4: Gonococcal resistance  
A.5: Quinolone resistant enterobacteriaceae in community  
A.6: *Salmonella* and *Shigella*  
A.7: *Pneumococcus*  
Metrics - eventually as defined by GLASS: rates, syndrome based approach, potentially aggregated in an index. Separate for community and hospital.  
A.8: % of *E.coli* susceptible to a panel of antimicrobials.  
A.9: Rate of ESBL producing *E.coli* in people, animals and environment. |
| **Patterns and trends in resistance in animal production sectors** | **Short term** (available in most countries within 5 years)  
A.10: Proportion of countries collecting/monitoring ESBL producing commensal *E. coli* (in healthy animals\(^{16}\) at slaughter) in priority food producing species.  
A.11: Actual prevalence levels of ESBL in commensal *E. coli* from food producing animal species, as determined from national data.  
A.12: Number of countries collecting antimicrobial sensitivity test data on at least one bacterial species for aquaculture.  
**Longer term** (available in most countries within 10 years)  
A.13: Change in resistance rates for ESBL/multidrug-resistant commensal *E. coli* (to a defined list of AMs) from priority food producing species.  
A.14: Number of countries monitoring ESBL commensal *E. coli* in major food commodities of non-animal origin. |

---

\(^{16}\) *Countries provide relevant data for their priority food producing species (e.g. prioritization based on production levels)*
<table>
<thead>
<tr>
<th>Result level</th>
<th>Proposed indicators: Global level</th>
</tr>
</thead>
</table>
| **General outcome**<br>B: more appropriate use of antimicrobials (with access when needed) and less inappropriate use | **B.1**: Level and trends in human consumption of access, watch and reserve antimicrobials, and the ratio between these, analysed by region and for countries with highly inequitable access.  
**B.2**: Number of countries achieving national targets for antimicrobial consumption/use (and number above global target if one is set).  
**B.3**: Equity index of access by country (like a Gini coefficient, to be defined).  
**B.4**: Access to AMs when needed: Proportion of health facilities that have a core set of relevant essential medicines available and affordable on a sustainable basis. (SDG indicator 3.b.3, with Access antibiotics disaggregated).  
**B.5**: Affordability of key products – e.g. number of countries with price of a course of a specific, generic second line antibiotic is more than 7 days’ wages.  
**B.6**: Global shortages of specific classes of antimicrobials as shown by UNICEF inability to procure. |

| Short term (within 5 years) | **B.7**: % or number of countries with specific legislation on use of medically important antimicrobials for growth promotion in food producing animals.  
**B.8**: % or number of countries that measure sales/use of medically important antimicrobials for growth promotion in food producing animals.  
**B.9**: Trends in use of medically important antimicrobials used for growth promotion in food producing species, weighted by biomass of species (mg/kg).  
**Longer term** (available in most countries within 10 years) | **B.10**: Reduction in volume of sales/use of medically important antimicrobials in food producing species weighted by biomass of species (mg/kg), focusing on a reduction in the proportion classified as the highest priority Critically Important Antimicrobials.  
**B.11**: Number of countries that have systems to collect information on antimicrobial use in plant production.  
**B.12**: Number of countries that regulate which antimicrobials can be used in plant production. |

---

17 See footnote Error! Bookmark not defined.
<table>
<thead>
<tr>
<th>Result level</th>
<th>Proposed indicators: Global level</th>
</tr>
</thead>
</table>
| **Overarching Goal:** lower impact from infectious diseases on human and animal health. | OG.1: Incidence of selected infections including resistant infections using same list as for General Outcome A, analysed by region; trends for large population countries; trends for all countries for which data is available. Denominators: Per 100,000 population, per inpatient day, or per hospital admission (or per device day for device associated infections).  
OG.2: Morbidity due to AMR: Prevalence of hospitalizations due to overall AMR infections or selected AMR infections (e.g. ESBL-producing *E.coli* & *K.pneumoniae* bacteremia) according to ICD-codes per 1,000 hospitalizations.  
OG.3: Modelled burden of disease linked to AMR.  
OG.4: Modelled estimates of mortality attributed to resistant infections e.g. for bloodstream and/or cerebrospinal fluid infections caused by carbapenem-resistant Enterobacteriaceae (CRE), vancomycin resistant enterococci (VRE), *Clostridium difficile* and MRSA, per 100,000 per year.  
OG.5: Estimated number of deaths attributable to failure of antibiotic therapy due to overall antibiotic resistance or selected AMR infections (e.g. ESBL-producing *E.coli* & *K.pneumoniae* bacteremia) according to ICD-codes per 1,000 hospitalizations, for countries with data available.  
OG.6: Modelled estimate of neonatal deaths attributable to resistance.  
OG.7: Estimated change in mortality burden related to GAP implementation, e.g. modelled estimates of reductions in infections and related mortality due to use of new products, by disease.  
OG.8: Modelled impact of resistance on key animal diseases that are treated with antimicrobials.  
OG. 9: Modelled impact on animal health, welfare and production of changes made to production practices (e.g. husbandry, biosecurity etc.) to minimise AM use. |
| **GAP Goal: continued ability to treat and prevent infectious diseases with effective and safe medicines** | GG.1: Critical gaps: resistant infections that lack easy diagnostics, effective preventive and/or treatment options (available or in the R&D pipeline).  
GG.2: Pathogens with low drug resistance, e.g. status of resistance for selected classes of antibiotics.  
GG.3: Vaccines available to control animal diseases that reduce the use of antimicrobials.  
GG.4: Vaccine coverage for key animal diseases for which vaccines would reduce antimicrobial use. |